Energy & Environmental Law Adviser
Product Liability & Mass Torts Blog
Employment Law Landscape
Imron T. Aly is a trial lawyer who serves as lead counsel for clients on dozens of matters, and has first-chaired more than 10 trials. Imron is co-leader of Schiff Hardin’s Intellectual Property Group and co-chair of the firm's Hatch-Waxman and Biosimilars patent litigation team. His practice is focused on patent infringement litigation. He has litigated and tried patent infringement and other IP matters related to pharmaceuticals, medical implants and devices, DNA arrays, mechanical production assemblies, computer business methods, and financial trading systems. Clients and leading industry publications describe Imron as a prepared courtroom advocate whose “tenacity sets him apart,” who “stands out for his pure advocacy skills,” and “is an untiring advocate for his clients’ cause.”
Prior to joining Schiff Hardin, Imron was an intellectual property partner in the Chicago office of an international law firm.
Intellectual Property Practice Group Co-Leader Imron Aly has joined the advisory board for the Center for Biosimilars, an online resource for emerging pharmaceutical biotechnology that discusses the current landscape for advanced health care management with top industry thought leaders.
Center for Biosimilars
Managing Intellectual Property Innovation and Litigation Summit 2019
Schiff Hardin LLP is proud to announce that the firm and three of its attorneys have been ranked in the eighth edition of IAM Patent 1000: The World’s Leading Patent Professionals.
Schiff Hardin is pleased to announce that the firm has been ranked as ‘Recommended’ by Managing Intellectual Property magazine in the Illinois IP Stars Patent Contentious category, which includes dispute resolution work, litigation and enforcement, as well as Hatch-Waxman, International Trade Commission, and multinational litigation work.
Schiff Hardin is pleased to announce that four practice areas and 23 attorneys have been recognized in the 2019 edition of Chambers USA, a leading legal industry ranking.
Schiff Hardin LLP is pleased to have 95 attorneys named to the 2019 Leading Lawyers list.
Two partners were recognized among “best of the best” on 2019 Illinois Top Lists
The Pharma Letter
As the government shutdown stretches on, pharmaceutical companies must manage the partial shutdown of the U.S. Food and Drug Administration (FDA).
Imron has represented indigent clients in trademark and copyright, contract dispute, landlord-tenant, prisoner rights, and elder abuse matters.
Managing Intellectual Property
Chambers & Partners
Law Bulletin’s Illinois Leading Lawyers Network
LMG Life Sciences
Legal Media Group
IAM Patent 1000
Crain’s Chicago Business
Law Bulletin's Illinois Leading Lawyers Network
BTI Power Ranking
Globe Business Media Group's The World’s Leading Patent Practitioners (2014, 2015)
Chambers USA: America’s Leading Lawyers for Business (2014)
Euromoney's Benchmark Litigation (2013, 2014)
Shortly after approving the first biosimilar under the abbreviated approval pathway created by the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”), the FDA has recently issued 3 final guidances regarding biosimilars. Biological products, or “biologics,” are pharmaceutical products created from biological sources. Unlike chemically synthesized pharmaceuticals, biologics are isolated from natural sources, and... Continue Reading
Aly and Patel are Strategic, Must-Have Advisers Who Bring Generic Drugs to Market Copy: Intellectual Property Practice Group Co-Leaders Imron Aly and Sailesh Patel were featured in Leading Lawyers Magazine—2018 Business Edition for their successful track record in challenging giant pharmaceutical companies to bring generic drugs to the marketplace.
Schiff Hardin’s pharma and life sciences patent litigation team, led by partner Imron T. Aly, recently secured a preliminary injunction in federal court. Representing generic drug manufacturer Fresenius Kabi USA, LLC, our team convinced the judge to bar our client’s competitor from launching a generic version of levothyroxine, our client’s patented treatment formulation.